Today: 13 June 2026
Centene stock slides as 2026 profit view beats estimates but revenue forecast falls short
6 February 2026
1 min read

Centene stock slides as 2026 profit view beats estimates but revenue forecast falls short

New York, Feb 6, 2026, 15:30 EST — Regular session

Centene Corp (CNC.N) shares dropped 5.7% to $37.64 in Friday afternoon trade, having earlier hit a session low of $35.31. The move comes as investors sift through the insurer’s updated 2026 outlook. Molina Healthcare (MOH.N) slid roughly 28%, dragging on the rest of the U.S. managed-care sector.

Why does this reaction matter? For government-focused health insurers, it’s all about a single issue: is medical spending settling down, or does it keep outpacing what they’re getting from state and federal payers?

Centene’s update comes as the sector faces turbulence, investors dumping shares on even a whiff that rates haven’t caught up with care demand in Medicaid and Affordable Care Act plans.

Centene put out a 2026 adjusted profit forecast topping $3 a share, clearing the bar set by Wall Street. But revenue came in light: the company projected $186.5 billion to $190.5 billion, missing analysts’ $193.43 billion consensus, per LSEG. Baird’s Michael Ha wrote, “We expect the magnitude of Molina’s unfavorable earnings to prevent Centene from moving higher today”—though some on the Street see Molina’s issues as more idiosyncratic. Reuters

Centene posted an adjusted fourth-quarter loss of $1.19 a share on $49.7 billion in revenue, with its health benefits ratio landing at 94.3%. Looking ahead to 2026, the company projected adjusted EPS topping $3.00 and a health benefits ratio between 90.9% and 91.7% for the full year. CEO Sarah London pointed to “positive momentum” by the end of 2025, attributing it to the company’s moves around Marketplace profitability and Medicaid stability. Investor Relations | Centene Corporation

The real pivot here: health-benefits costs. Just a couple of percentage points up or down, and you’re looking at either solid earnings or the threat of further cuts. That’s especially true for plans with pricing that only adjusts annually.

Centene’s Friday Form 8-K included both its earnings release and a 2026 guidance deck, according to the filing.

J.P. Morgan’s John Stansel said the results ought to “provide some relief” in the wake of Molina’s warning, according to Healthcare Dive. The outlet also pointed out Centene holds the top spot among U.S. Medicaid managed-care insurers and leads all providers on Affordable Care Act exchanges. Healthcare Dive

Still, it’s a shaky setup. Should medical-cost trends remain elevated through spring — or if funding and rate changes don’t keep up with utilization — Medicaid and ACA exchange plan margins could shrink in a hurry, making guidance outdated almost overnight.

The next key date for investors: Centene’s first-quarter 2026 report, set for April 28. The earnings event is on the calendar.

Stock Market Today

  • Delek US Holdings (DK) Shares Show Slight Undervaluation After Strong Gains
    June 12, 2026, 10:22 PM EDT. Delek US Holdings (DK) stock trades at $47.22, reflecting a 7.61% gain over one month and a 138.48% one-year total shareholder return, signaling strong momentum. Despite this, the stock is assessed as 4.4% undervalued, with a fair value estimate of $49.38. The company's operational improvements via its enterprise optimization program (EOP) aim to boost cash flow by $130-$170 million annually, potentially enhancing net margins and free cash flow from mid-2025. Market optimism is tempered by risks including refining margin compressions, ongoing losses, and high capital expenditure burden. Investors are encouraged to weigh the balance of potential rewards against these risks for portfolio decisions.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Robinhood stock jumps nearly 15% as bitcoin rebounds; earnings next week in focus
Previous Story

Robinhood stock jumps nearly 15% as bitcoin rebounds; earnings next week in focus

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL
Next Story

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL

Go toTop